Table 2 Characteristics of studies evaluating effect of metformin on IL-6 levels of polycystic ovary syndrome
From: Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review
Author and year of publication | No. of cases | No. of controls | Dosage of metformin | IL-6 level before treatment (pg/ml) | IL-6 level after treatment (pg/ml) | P | Outcomes |
|---|---|---|---|---|---|---|---|
Mohlig et al. 2004 [5] | 9 obese, insulin-resistant PCOS patients | 20 health women | 850 mg, three times daily, 6 months | 1.72 ± 0.30 | 1.91 ± 0.31 | 0.515 | After 6 months therapy, IL-6 concentrations remained largely unchanged |
Jakubowska et al. 2008 [17] | 29 obese PCOS patients | 29 healthy, premenopausal volunteers matched for BMI. | 500 mg, twice daily, 6 months | 34.32 ± 8.28 | 33.36 ± 8.28 | >0.05 | plasma IL-6 levels did not change during therapy |
Luque-Ramirez et al. 2010 [16] | 19 PCOS women | 18 health women | 850 mg, twice daily, 24 weeks | 1.0 ± 0.9 | 0.7 ± 0.5 | 0.56 | The decrease observed in serum IL-6 levels in the patients treated with metformin correlated inversely with the increase in the insulin sensitivity index and directly with the decrease in the insulin secretion index |
Lin et al. 2011 [6] | 129 PCOS women | 109 control women | 500 mg, three times daily, 12 weeks | 28.05 ± 3.26 | 22.04 ± 2.76 | 0.0342 | There was a significant decrease in IL-6 level after metformin treatment in PCOS women. |
Ciaraldi et al. 2013 [18] | 5 PCOS women | 7 control women | 2 g/d, 6 months | Data was not showed | Data was not showed | Data was not showed | Treatment-related reductions in IL-6 levels were significantly correlated with falls in fasting insulin |